The 27 references in paper E. Sokova A., N. Bunyatyan D., I. Mazerkina A., O. Demidova A., T. Aleksandrova V., Е. Сокова А., Н. Бунятян Д., И. Мазеркина А., О. Демидова А., Т. Александрова В. (2018) “Клинические исследования лекарственных средств у беременных: отношение ожидаемой пользы к возможному риску? // Clinical trials in pregnancy: evaluation of benefit/risk?” / spz:neicon:vedomostincesmp:y:2015:i:4:p:26-31

1
Briggs GG, Freeman RK, Yaffe SJ. A reference guide to fetal and neonatal risk. Drugs in pregnancy and lactation. 9th edition. Philadelphia: Lippincott Williams&Wilkins; 2014.
(check this in PDF content)
2
Feghali MN, Mattison DR. Clinical Therapeutics in Pregnancy (Review Article). Journal of Biomedicine and Biotechnology 2011; 783528.
(check this in PDF content)
3
Hill CC, Pickinpaugh J. Physiologic changes in pregnancy. Surgical Clinics of North America 2008; 88(2): 391–401.
(check this in PDF content)
4
Adam MP, et al. Evolving knowledge of the teratogenicity of medications in human pregnancy. Am J Med Genet. 2011; 157: 175–82.
(check this in PDF content)
5
Andrew MA, Easterling TR, Carr DB, Shen D, Buchanan ML. Amoxicillin pharmacokinetics in pregnant women: modeling and simulations of dosage strategies. Clinical Pharmacology and Therapeutics 2007; 81(4): 547–56.
(check this in PDF content)
6
Hebert MF, Ma X, Naraharisetti SB, Krudys KM, Umans JG, Hankins GD, Vicini P. Obstetric-Fetal Pharmacology Research Unit Network. Are we optimizing gestational diabetes treatment with glyburide? The pharmacologic basis for better clinical practice. Clinical Pharmacology and Therapeutics 2009; 85(6): 607–14.
(check this in PDF content)
7
Chambers CD, Polifka JE, Friedman JM. Drug safety in pregnant women and their babies: ignorance not bliss. Clinical Pharmacology and Therapeutics 2008; 83(1):181–3.
(check this in PDF content)
8
Guidance for Industry Pharmacokinetics in Pregnancy – Study Design, Data Analysis, and Impact on Dosing and Labeling. U.S. Department of Health and Human Services Food and Drug Administration Center for Drug Evaluation and Research (CDER). October 2004.
(check this in PDF content)
9
On Amendments to the Federal Law «On Circulation of Medicines». Federal Law No 429-FZ, 12.22.2014 (in Russian).
(check this in PDF content)
10
Wood SF, Blehar MC, Mauery R. Policy Implications of a New National Institutes of Health Agenda for Women's Health Research, 2010–2020. Women's Health Issues 2011; 21(2): 99–103.
(check this in PDF content)
11
Blehar MC, Spong C, Grady C, Goldkind SF, Sahin L, Clayton JA. Enrolling pregnant women: issues in clinical research. Women's health issues: official publication of the Jacobs Institute of Women's Health 2013; 23(1): 39–45.
(check this in PDF content)
12
The Council for International Organizations of Medical Sciences (CIOMS) in collaboration with the World Health Organization (WHO), Guideline 17.
(check this in PDF content)
13
Lyerly AD, Little MO, Faden R. The Second Wave: toward responsible inclusion of pregnant women in research. International Journal of Feminist Approaches to Bioethics 2008; 1(2): 6–22.
(check this in PDF content)
14
Goldkind SF, Sahin L, Gallauresi B. Enrolling pregnant women in research – lessons from the H1N1 influenza pandemic. New England Journal of Medicine 2010; 326(24): 2241–3.
(check this in PDF content)
15
Levine RJ. IRB perspective on inclusion of pregnant women in clinical research. Issues in Clinical Research: Enrolling Pregnant. A workshop report. 2011.
(check this in PDF content)
16
McCullough LB, Coverdale JH, Chervenak FA. A comprehensive ethical framework for responsibly designing and conducting pharmacologic research that involves pregnant women. American Journal of Obstetrics and Gynecology 2005; 193(3, part 2): 901–7.
(check this in PDF content)
17
Macklin R. The art of medicine: Enrolling pregnant women in biomedical research. The Lancet 2010; 375: 632–3.
(check this in PDF content)
18
Guideline on the exposure to medicinal products during pregnancy: need for post-authorisation. EMEA/CHMP/313666/2005, London, 14 November, 2005. R E F E R E N C E S
(check this in PDF content)
19
Advances in FDA’s Safety Program for Marketed Drugs. Drug Safety Report. April 2012. Center for Drug Evaluation and Research U.S. Food and Drug Administration U.S. Health and Human Services A.
(check this in PDF content)
20
Sim SC, Ingelman-Sundberg V. Pharmacogenomic biomarkers: new tools in current and future drug therapy. Trends Pharmacol Sci. 2011; 32: 72–81.
(check this in PDF content)
21
Mattison DR. Clinical Pharmacology during pregnancy. Elsevier; 2013.
(check this in PDF content)
22
Atkinson D, Brice-Bennet S, D’Souza S.W. Antiepileptic Medication During Pregnancy: Does Fetal Genotype Affect Outcome? Pediatric research 2007; 62(2): 120–7.
(check this in PDF content)
23
Пастернак ЕЮ, Аляутдин РН, Романов БК. Трансформация взглядов на тератогенность противоэпилептической терапии. Безопасность и риск фармакотерапии 2014; (4): 12–17.
(check this in PDF content)
24
Isoherranen N, Kenneth E. Drug Metabolism and Transport During Pregnancy: How Does Drug Disposition Change during Pregnancy and What Are the Mechanisms that Cause Such Changes? Drug Metab Dispos. 2013; 41: 256–62.
(check this in PDF content)
25
Landau R. Pharmacogenetics and obstetric anesthesia. Anesthesiol Clin. 2008; 26(1): 183–95.
(check this in PDF content)
26
Sim SC, Ingelman-Sundberg V. Pharmacogenomic biomarkers: new tools in current and future drug therapy. Trends Pharmacol Sci. 2011; 32: 72–81.
(check this in PDF content)
27
Food and Drug Administration. Health organizations to study safety of medications taken during pregnancy. FDA News Release. Dec 30, 2009. Available from: www.fda.gov/NewsEvents/Newsroom/ PressAnnouncements/2009/ucm195934.htm. 19. Advances in FDA’s Safety Program for Marketed Drugs. Drug Safety Report.
(check this in PDF content)